AI

VUNO’s AI solution certified to help diagnose infectious respiratory diseases


VUNO mentioned it has obtained the Ministry of Meals and Drug Security certification for VUNO Med-LungQuant, a man-made intelligence (AI)-based lung computed tomography (CT) quantification.


The Ministry of Food and Drug Safety has certified VUNO's AI solution that can help diagnose respiratory infectious diseases.
The Ministry of Meals and Drug Security has licensed VUNO’s AI answer that may assist diagnose respiratory infectious illnesses.


The answer routinely analyzes lung CT pictures based mostly on AI to phase attribute areas in CT pictures and gives visualization and quantification info for every detailed space. It thus helps healthcare suppliers decide the sort and severity of lung illness.


In keeping with the product’s approval, the settlement between the answer and the thoracic radiologist within the lung CT picture of the area of curiosity mark was greater than 90 %, proving excessive efficiency. VUNO has developed the supply expertise for this answer by the Ministry of Science and ICT’s challenge to foster world corporations specializing in software program.


Because the Covid-19 virus unfold in early 2020, physicians found irregular findings comparable to ground-glass opacity and consolidation in lung CT of contaminated sufferers, rising the necessity for extra CT image-based screening or follow-up remark.


Accordingly, VUNO optimized the unique expertise developed to exactly analyze and diagnose present lung illnesses to quantify newly rising infectious illnesses. By way of this, the corporate accomplished the event of the answer by including detailed evaluation and visualization features for every lung space for quicker analysis.


Hospitals can use VUNO Med-LungQuant for screening lung illnesses exact analysis of the severity and course of respiratory illnesses based mostly on the extent or distribution of lesions.


Additionally, as the answer can quantify most lung illness patterns, the corporate expects it to be a helpful screening instrument for brand new respiratory infectious illnesses sooner or later.


“The corporate developed VUNO Med-LungQuant as part of the nationwide challenge and obtained certification by proving its scientific effectiveness as an efficient instrument to help within the screening and follow-up of respiratory infectious illnesses,” VUNO CEO Lee Ye-ha mentioned. “The corporate hopes that the answer will relieve the burden of busy medical employees in additional medical fields and contribute to scarce medical assets.”

Related posts

Major Hindu Organization to Test AI-Powered Weapons Detection System

Chris

11.2 Ventures Brings on Sudhir Ravi to Manage the Commercialization of the Venture Studio’s AI Products

Chris

Clearview AI on track to win U.S. patent for facial recognition technology

Chris

Leave a Comment